Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Allscripts Healthcare Solutions Shares Popped

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of health care information technology company Allscripts Healthcare Solutions (Nasdaq: MDRX  ) rallied as much as 24% today after announcing its second-quarter earnings results.

So what: For the quarter, Allscripts reported a 3.7% increase in revenue to $370 million, which was right in line with analysts' projections, and a profit of $0.16, which fell $0.02 shy of expectations. Overall bookings fell $50 million year over year while gross profit dipped by 530 basis points. The big news moving the stock higher relates to Allscripts guidance which calls for the company to earn $0.77-$0.83 in EPS for fiscal 2012, which is notably higher than Wall Street's consensus estimate of $0.74.

Now what: But don't get too excited. Allscripts also aggressively repurchased $225 million worth of stock during the quarter, or 21 million shares. The boost in annual EPS merely reflects the fact that Allscripts reduced its outstanding share count and not from actual growth. Here's yet another case of a company trying to mask weak growth behind share buybacks. Just as we saw in the first quarter, operating expense growth vastly outpaced revenue growth (12.4% vs. 3.7%) and this marked the second-straight quarterly EPS miss. With a management shake-up still fresh in everyone's minds, I'm not buying into today's optimism and would prefer to stay away from Allscripts for the time being.

Craving more input? Start by adding Allscripts Healthcare Solutions to your free and personalized Watchlist so you can keep up on the latest news with the company.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1979254, ~/Articles/ArticleHandler.aspx, 10/21/2016 11:08:54 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,068.63 -93.72 -0.52%
S&P 500 2,136.15 -5.19 -0.24%
NASD 5,245.27 3.44 0.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 10:53 AM
MDRX $12.40 Down -0.44 -3.39%
Allscripts CAPS Rating: ***